IMPEDIMED LIMITED — Board/Management Information 2013

Mar 17, 2013

==> picture [81 x 92] intentionally omitted <==

ASX ANNOUNCEMENT

IMPEDIMED ANNOUNCES MANAGEMENT CHANGES

18 March 2013

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“ImpediMed”) announces the resignation today of Peggy Brooker, COO and CFO.

“Peggy has been a tireless force in orchestrating the global financial administration and back office operating functions of ImpediMed, first as VP of Global Finance, then CFO, and finally COO and CFO to the Company,” stated Richard Carreon, CEO. “In her 3+ years at ImpediMed, she built an outstanding team of professionals, which leaves us in an extremely positive position to manage all projects going forward. Nonetheless, she will be missed.”

“The Company is thankful for Ms. Brooker’s dedication and hard work, and we wish her every success in her future endeavors,” said Carreon.

In addition, the U.S. Headquarters has completed the final phase of its strategic realignment, which includes the departure of ImpediMed’s Sr. VP of Sales and Marketing, William Gearhart, as well as Sr. VP of Business Development, Jack Butler, and two other professionals. “I thank these individuals for helping move the company through its early startup phase and wish them all the best.”

Additionally, Morten Vigeland has been promoted to the position of Vice President of Global Finance. “Morten’s previous financial expertise as a CFO of a medical device company, and his industry knowledge, will continue to enhance our financial and operational capabilities both in the U.S. and Australia,” said Carreon.

“Our realignment efforts have already delivered significant value in terms of dramatically lowering our cost structure, while driving double digit growth in our core lymphoedema business. Although we will continue to focus on disciplined financial controls, we will be accelerating our investments in those initiatives that offer the greatest opportunity for growth. We believe these actions will better position ImpediMed to create value for our shareholders and improve the quality of life for patients,” according to Carreon.

For further information contact: Richard Carreon, ImpediMed CEO T: +1 (858) 412-0200

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au